Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
August 23 2022 - 7:13AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
August 23, 2022
Commission File Number: 001-39363
IMMATICS N.V.
Paul-Ehrlich-Straße 15
72076 Tübingen, Federal Republic of Germany
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION
CONTAINED IN THIS REPORT ON FORM 6-K
On
August 23, 2022, Immatics N.V. (the “Company” or “Immatics”) announced the treatment of the first patient in
its Phase 1b expansion cohort (NCT03686124) evaluating IMA203CD8, the company’s 2nd generation TCR-T monotherapy approach where
a proprietary CD8αβ co-receptor is added to PRAME-specific IMA203 T cells. The IMA203CD8 Phase 1b dose expansion cohort is
expected to enroll up to 24 patients with different types of solid tumors across several clinical trial sites in the U.S. and in Germany.
In
connection with the foregoing, the Company issued a press release, a copy of which is attached hereto as Exhibit 99.1.
INCORPORATION
BY REFERENCE
This
Report on Form 6-K (other than Exhibit 99.1) shall be deemed to be incorporated by reference into the registration statements on Form
F-3 (Registration Nos. 333-258351 and 333-240260) of Immatics N.V. and to be a part thereof from the date on which this report is filed,
to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
Exhibit No. |
Description |
99.1 |
Press release dated August 23, 2022
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
IMMATICS N.V. |
Date: August 23, 2022 |
|
|
By: |
/s/ Harpreet Singh |
|
Name: |
Harpreet Singh |
|
Title: |
Chief Executive Officer |
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Sep 2023 to Sep 2024